NASDAQ:KPRX Kiora Pharmaceuticals Q3 2025 Earnings Report $2.68 -0.08 (-2.90%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Kiora Pharmaceuticals EPS ResultsActual EPS$0.01Consensus EPS -$0.72Beat/MissBeat by +$0.73One Year Ago EPSN/AKiora Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$0.75 millionBeat/MissN/AYoY Revenue GrowthN/AKiora Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/7/2025TimeBefore Market OpensConference Call DateFriday, November 7, 2025Conference Call Time6:00AM ETUpcoming EarningsKiora Pharmaceuticals' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Kiora Pharmaceuticals Earnings HeadlinesAditxt (NASDAQ:ADTX) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head-To-Head SurveySeptember 14, 2026 | americanbankingnews.comKiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 0.8% - Here's What HappenedSeptember 10, 2026 | americanbankingnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 21 at 1:00 AM | InvestorPlace (Ad)Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory AffairsSeptember 8, 2026 | finance.yahoo.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Kiora Pharmaceuticals (KPRX)August 9, 2026 | theglobeandmail.comKiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive PlanJune 11, 2026 | tipranks.comSee More Kiora Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kiora Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiora Pharmaceuticals and other key companies, straight to your email. Email Address About Kiora PharmaceuticalsKiora Pharmaceuticals (NASDAQ:KPRX) is a clinical-stage biotechnology company focused on developing therapies for serious ophthalmic diseases. The company’s research programs are designed to address conditions affecting the retina and other parts of the eye, including diseases for which treatment options remain limited. Kiora’s lead candidate, KIO-301, is an investigational small-molecule therapy being developed to restore or improve visual function in patients with inherited retinal diseases, including retinitis pigmentosa. The company is also developing KIO-104, an investigational therapy intended to treat noninfectious uveitis, an inflammatory eye condition. Based in the United States, Kiora conducts its drug-discovery and clinical-development activities primarily through collaborations and clinical studies. The company was formed through the combination of EyeGate Pharmaceuticals and Jade Therapeutics and adopted the Kiora Pharmaceuticals name in 2020. Kiora’s programs remain in development, and the company does not have widely marketed commercial products.View Kiora Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep WinningJ.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to Growth Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
